David C. Metz, MBBCh (MD equivalent)
Professor CE of Medicine
Director, Acid Peptic Disorders Specialty Program, Digestive and Liver Center, Hospital of the University of Pennsylvania
Co-Director, Neuroendocrine Tumor Center, University of Pennsylvania Perelman School of Medicine
Full Clinical Member, Abramson Cancer Center, Cancer Therapeutics Program
Department: Medicine
Contact information
3400 Civic Center Boulevard
709 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
709 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
Office: 215-662-3541
Fax: 215-349-5915
Fax: 215-349-5915
Email:
david.metz@uphs.upenn.edu
david.metz@uphs.upenn.edu
Publications
Links
Search PubMed for articles
University of Pennsylvania Neuroendocrine Tumor Program
Penn Medicine Abramson Cancer Center
Penn Medicine Esophageal and Swallowing Disorders Program
Search PubMed for articles
University of Pennsylvania Neuroendocrine Tumor Program
Penn Medicine Abramson Cancer Center
Penn Medicine Esophageal and Swallowing Disorders Program
Education:
HS
King David High School , 1975.
MD
University of Witwatersrand Medical School, Johannesburg, South Africa. , 1982.
Permanent linkHS
King David High School , 1975.
MD
University of Witwatersrand Medical School, Johannesburg, South Africa. , 1982.
Selected Publications
Lau CT, Gefter WB, Metz DC: Radiographic appearance of a catheter-free wireless esophageal pH probe. Am J Roentgenol 184: S40-42, 2005.Shih GL, Brensinger C, Katzka DA, Metz DC: Postprandial esophageal integrated acidity is a reliable predictor of GERD. Aliment Pharmacol Therap 21: 1475-1482, 2005.
Metz DC, Miner PB, Heuman DM, Chen Y, Sostek M: Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-esophageal reflux disease. Aliment Pharmacol Therap 22: 813-821, 2005.
Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W, Pisegna JR: Three year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Therap 23: 437-444, 2006.
Pratha V, Hogan DL, Lynn RB, Field B, Metz DC: Intravenous Pantoprazole as Initial Treatment in Patients With Gastroesophageal Reflux Disease and a History of Erosive Esophagitis: A Randomized Clinical Trial. Dig Dis Sci 51: 1595-1601, 2006.
Blonski WC, Shih GL, Brensinger CM, Katzka DA, Metz DC: Analysis of the acidity index and integrated intragastric acidity in 645 patients presenting with gastroesophageal reflux disease symptoms. Sc J Gastroenterol 41: 382-389, 2006.
Yang YX, Lewis JD, Epstein S, Metz DC: Chronic proton pump inhibitor therapy and hip fracture risk. JAMA 296: 1595-1601, 2006.
Lewis JD, Strom BL, Kimmel SE, Farrar J, Metz DC, Brensinger C, Nessel L, Localio AR: Predictors of recall of over-the-counter and prescription non-steroidal anti-inflammatory drug exposure. Pharmacoepidemiol Drug Saf 15: 39-45, 2006.
Howden C, Metz DC, Hunt B, Majid V, Kukulka M, Amer F, Samra N. : Dose-Response Evaluation of the Antisecretory Effect of Continuous Infusion Intravenous Lansoprazole Regimens over 48 Hours. Aliment Pharmacol Therap 23: 975-984, 2006.
Metz DC, Amer F, Hunt B, Majid V, Kukulka M. : Lansoprazole Regimens That Sustain Intragastric pH >6: An Evaluation of Intermittent Oral and Continuous IV Infusion Dosages. Aliment Pharmacol Therap 23: 985-995, 2006.